Vitroprobe Analytics performs biomolecular analysis at the atomic scale to help design the pharmaceutical drugs of tomorrow. The development of new effective pharmaceutical drugs to fight disease is a slow and expensive process. Successful drug design relies on a profound understanding of the interactions between drug candidates and their target molecules in the body. The company has developed a unique platform to analyze target molecular structure in3D with simultaneous identification of individual constituent atoms. With the novel patented technique drug targets can be examined one atom at a time, thereby enabling fine-tuning of new pharmaceutical substances. The technology is the result of an interdisciplinary research program at Chalmers University of Technology.